Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Lapatinib Plus Chemotherapy in HER2+ Inflammatory Breast Cancer
NCT00756470Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2008
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in inflammatory breast cancer (IBC), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2008; status: terminated.
02
Drugs
lapatinib
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT00756470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00756470.